Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Initial List Of US Essential Medicines Focuses On Acute Care

Executive Summary

US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.

You may also be interested in...



‘Temperature Abuse’ Heated US Drug Recalls To Record Level In FY2022, FDA Finds

Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.

‘Temperature Abuse’ Led Drug Recalls To New Heights In FY 2022, US FDA Finds

Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.

Drug Shortages Back In US Congressional Spotlight

Drug shortages were a significant focus of legislative attention in the US before the COVID-19 pandemic, and Congress is not likely to drop the issue now that the public health emergency is winding down.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel